We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · August 27, 2022

Deucravacitinib vs Placebo and Apremilast in Moderate to Severe Plaque Psoriasis

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial
J Am Acad Dermatol 2022 Jul 09;[EPub Ahead of Print], AW Armstrong, M Gooderham, RB Warren, KA Papp, B Strober, D Thaçi, A Morita, JC Szepietowski, S Imafuku, E Colston, J Throup, S Kundu, S Schoenfeld, M Linaberry, S Banerjee, A Blauvelt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading